申请人:Pfizer Inc.
公开号:US05242911A1
公开(公告)日:1993-09-07
A series of bridged bicyclic imide compounds having a 4-(4-[2-pyrimidinyl]-1-piperazinyl)butyl group attached to the imide nitrogen are useful for alleviating the symptoms of anxiety and depression in human subjects.
一系列具有连接到亚酰胺氮原子上的4-(4-[2-嘧啶基]-1-哌嗪基)丁基基团的桥联双环亚酰胺化合物对缓解人类主体的焦虑和抑郁症状有用。